Table 3

Apoptosis/PCNA ratio for cancer cells after therapy with monoclonal antibody C225 and/or paclitaxel

TherapyApoptosis index,a mean ± SD (range) (per ×200 field)PCNA index,a mean ± SD (range) (per ×200 field)Apoptosis/PCNA ratio,b (per ×200 field)
Pretreatment CTRLc2 ± 1 (1–3)303 ± 98 (200–444)0.7
CTRL (PBS)4 ± 1 (2–7)248 ± 68 (199–363)1.6
Paclitaxel14 ± 4d (11–18)70 ± 11d (55–84)20.0d
C22511 ± 2d (9–13)87 ± 16d (69–109)12.6d
Paclitaxel/C22525 ± 6d,e (19–33)30 ± 9d,e (20–40)83.3d
  • a The apoptosis index for cancer cells, determined by TUNEL assay, and cell proliferation, determined by IHC with PCNA, are expressed as the average of five highest areas identified within a single ×200 field.

  • b Apoptosis/PCNA ratio: mean percentage of the number of apoptotic cells divided by the number of PCNA-positive cells.

  • c CTRL, control.

  • d,e Mann-Whitney statistical comparison:

  • d P < 0.005 vs. CTRL;

  • e P < 0.005 vs. both single therapy groups with either paclitaxel or C225.